Conditions: Carcinoma, Renal Cell
Keywords: AG-013736 RCC Phase 2
Enrollment: 64
Healthy volunteers: no

Brief summary:
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: AG-013736
Intervention descriptions: intervention 1: AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.

Number of cycles: until progression or unacceptable toxicity develops.

Protocol document: